MedTrace Logo

Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.

NCT07400809 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2026-02-17

No results posted yet for this study

Summary

Systemic chemotherapy with or without palliative radiation represents the current standard of care in patients with recurrent or metastatic cervix cancer. In addition, pelvic radiotherapy including brachytherapy is also recommended. There is no consensus on the treatment of metastatic site in patients with oligo-metastatic or oligo-recurrent cervix cancer. Also, it is not clear if addition of local treatment to systemic chemotherapy benefits all patients with metastatic disease or a select few with limited systemic disease burden. It's presently unclear which patients derive maximum benefit with integration of radiation at both primary and metastatic site, who develop infield recurrence if performing salvage surgery, locally directed treatments or re-irradiation in addition to systemic chemotherapy improves overall outcomes. The heterogeneity in clinical practice provides an important opportunity to develop a framework for data collection and future studies within such subgroup of patients. In this retrospective study, we aim to determine overall survival, Infield progression free survival, overall progression free survival, dose response relationship of nodal and visceral progressions, and within setting of re-irradiation (infield progressions), severe adverse events and toxicity, risk groups identification, a nomogram which correlates risk groups with expected outcomes, and framework for tissue collection for translational research Investigators will record the parameters in a predesigned proforma without including personal identifiers.

Conditions

  • Chemotherapy
  • Treatment Compliance
  • Radiotherapy
  • Cervix Cancer
  • Surgery
  • Recurrent
  • Metastasis

Interventions

OTHER

Not applicable- observational study

Not applicable- observational study

Sponsors & Collaborators

Principal Investigators

  • Dr. Supriya Chopra, MD · ACTREC, Tata Memorial Centre, Navi Mumbai India

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-23
Primary Completion
2027-06-14
Completion
2027-06-14

Countries

  • India

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07400809 on ClinicalTrials.gov